Vynleads

Vynleads on the Support Gap After Stopping Weight Loss Medication

Rock Hill, S.C. – October 9, 2026 – Vynleads (OTCQB: VYND) today shared a behavior-change perspective on a pilot randomized trial published October 7, 2026 in Obesity Science & Practice, “Preventing Weight Regain After Glucagon-Like Peptide-1 Therapy Discontinuation: A Pilot Randomized Controlled Trial.” Researchers from Tufts University and the University of Texas Southwestern Medical Center report that adults who received structured support after stopping a GLP-1 medication had less weight gain over four months than those who received usual care.

What the Trial Found

In the trial, 39 adults with prior GLP-1-induced weight loss were randomized at the time they stopped the medication to four months of usual care (14 participants), a digital wellness application (12), or medically tailored meals (13). The paper’s graphical abstract identifies the application as Noom’s digital behavioral program. According to Newsweek, the application let participants self-monitor diet, exercise, and weight and offered education on factors that influence eating behavior, and participants were required to use it for at least 15 minutes a day; the medically tailored meals were dietitian-developed meals delivered to participants’ homes.

The study’s primary outcome was adherence and satisfaction, assessed by survey. The authors report that adherence, satisfaction, diet quality, and perceived health did not significantly differ by group, though some estimates suggested possible trends favoring the wellness application. For weight, an exploratory outcome measured monthly on validated Bluetooth scales, both support groups had less total weight gain than usual care. According to Wiley’s announcement of the paper, the usual-care group gained an estimated 10.75% of body weight over four months, compared with 3.60% in the wellness application group and 3.58% in the medically tailored meals group. The authors conclude that structured support “may attenuate early weight gain after GLP-1 cessation” and that larger, more diverse trials with longer follow-up and clinical outcomes are needed to confirm the results.

Corresponding author Kelseanna Hollis-Hansen, PhD, MPH, of the Tufts University Food is Medicine Institute, told Newsweek that “many people receive limited lifestyle and behavior-change support while taking GLP-1 medications,” and said structured support during the first year after stopping could help people build “sustainable habits around eating, physical activity, sleep, and self-monitoring.” She added that more research is needed to “determine the optimal amount of time.”

Vynleads is not a clinical organization, was not involved in the study, and its program was not one of the interventions tested. The company takes no position on any GLP-1 medication’s efficacy, safety, dosing, or appropriate use, on whether or when anyone should continue or stop a medication, or on the programs studied. Those decisions belong with each person and their care team. The company’s interest is narrower: the routines around food, movement, sleep, and follow-through that a person carries on their own.

Daily Structure, Not Willpower

“When someone’s care changes, the daily questions keep coming: what to eat this week, when to move, how to get back on track after a hard few days. Our job is to make the next practical step clear and doable on an ordinary day. That’s why our program is built around daily lessons and saved progress, and why our coach keeps the focus on what a person can do next, like planning a meal, fitting in a walk, or writing down questions for their next visit. We stay out of medication decisions entirely; those belong with each person and their care team. And we don’t treat a care change as a test of willpower. We design for it as a time when people may want more structure, not less.”

— Alex Mannine, Co-Founder and CEO, Vynleads

Related reading from the Vynleads library: how to keep weight off after GLP-1, what happens when you stop taking a GLP-1 medicine, a plain-language guide to the GLP-1 set point, and questions to discuss before making changes to long-term GLP-1 use.

Follow-Through as the Measure

For readers following the company, Vynleads reads the trial as a signal about a moment in care rather than about any one product. The paper notes analyses showing that 20%–50% of patients discontinue a GLP-1 within a year of starting the medication, and its authors write that few evidence-based strategies exist to support weight maintenance during that transition. In the company’s view, that makes the months after a care change a distinct point of need for lifestyle support, alongside the support people look for while they take a medication, which Vynleads discussed in its comments on daily structure around weight loss medication and the Medicare GLP-1 Bridge program.

The company also reads the trial’s limits as part of the signal. It was a pilot with 39 participants and four months of follow-up; its primary outcome, adherence and satisfaction, did not differ significantly by group, and weight was an exploratory measure. “A digital wellness application” in this trial meant one specific program with a daily-use requirement, not apps in general. In Vynleads’ reading, that is why employers, payers, and product teams evaluating support tools are likely to ask sharper questions: does the tool help someone complete the everyday actions a plan calls for, and how is that completion shown?

Vynleads’ positioning is built around that question: a non-clinical scope set by design, a structure-first 8-week program with daily lessons and saved progress rather than open-ended chat, lifestyle inputs rather than clinical records, human review and escalation paths behind the AI, and a direct-to-consumer wellness model that can sit beside whatever care plan a person already has. Done With Diabetes™ is a structured lifestyle and wellness program for adults with type 2 diabetes or prediabetes; it is not a GLP-1 maintenance program, and it gives no medication guidance.

What raises the bar, in the company’s reading, is evidence of follow-through: showing, with clear and honest measures, that people complete the everyday steps a program asks of them. Vynleads believes that is where support tools will increasingly be judged, and it is the standard the company is building toward, from its flagship Done With Diabetes™ program to its planned “Done With (DWX)” portfolio.

Where Done With Diabetes™ Fits

The Done With Diabetes™ program pairs a structured 8-week Success Blueprint with the Dr. Smith AI Wellness Coach: educational lifestyle support with human review and safety checks, never medical advice, built on the company’s AI coaching technology. It focuses on the everyday routines around food, movement, sleep, stress, and follow-up care, and it does not comment on, adjust, or second-guess medication. Learn more about Vynleads.

Resources:

Vynleads is not affiliated with Tufts University, the University of Texas Southwestern Medical Center, Wiley, Obesity Science & Practice, Newsweek, or Noom, or with any researcher quoted in this release, and Vynleads was not part of this trial. This commentary is a non-clinical business and behavior-change perspective; it takes no position on any GLP-1 medication, manufacturer, or the interventions studied, it does not characterize any medication’s efficacy, safety, dosing, or appropriate use, or whether or when to continue or stop one, and it is not medical advice. It makes no claim about weight, blood sugar, retention, or other outcomes for any Vynleads program. Medication decisions belong solely with each person and their qualified care team. Done With Diabetes™ provides educational lifestyle support for general wellness; it does not provide medical advice, diagnosis, or treatment.